Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1992-07-20
1993-12-14
Bernhardt, Emily
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514312, 544128, 546153, 546156, 564305, 564441, 564442, 568936, 568939, A61K 31535, A61K 3147, C07D40112, C07D41312
Patent
active
052703096
ABSTRACT:
4-Oxo-1,4-dihydroquinoline compounds having a 2-acidic group or a group convertible thereto in vivo, and their pharmaceutically acceptable salts, are potent specific antagonists of N-methyl-D-aspartate (NMDA) receptors and are therefore useful in the treatment of neurodegenerative disorders. 4-Oxo-1,4-dihydroquinoline compounds having a 2-acidic group or a group convertible thereto in vivo, other than carboxy or C.sub.1-6 alkoxycarbonyl, are novel compounds, as also are compounds of formula II ##STR1## wherein R.sup.2 represents carboxy or a group convertible thereto in vivo, R.sup.6 is hydrogen and R.sup.5 and R.sup.7 represent C.sub.1-6 alkyl or halogen, provided that R.sup.5 and R.sup.7 are not simultaneously chlorine or simultaneously bromine; a process for preparing the novel compounds is described, as also are pharmaceutical compositions containing the novel compounds.
REFERENCES:
patent: 4328230 (1982-05-01), Brown et al.
patent: 5026700 (1991-06-01), Harrison et al.
patent: 5028707 (1991-07-01), Nichols et al.
Evans, et al., Br. J. Pharmac., vol. 91 (1987) pp. 531-537.
Mutschler Arzneimittelwirkungen 5th Edition (1986), pp. 555-566.
Perkins, et al., Chem. Abs. 99, No. 25 (Dec. 19, 1983) p. 139, 206826b.
Neumuller Rompps Chemie-Lexikon (8th Ed.) 3 p. 2296 (1983).
Daeniker, et al., Chem. Abs. 54, No. 538 (1960).
Heindel, et al., J. Med. Chem. II, pp. 1218-1221 (1968).
Bernhardt Emily
DiPrima Joseph F.
Merck Sharp & Dohme Limited
North Robert J.
LandOfFree
Kynurenic acid derivatives useful in the treatment of neurodegen does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Kynurenic acid derivatives useful in the treatment of neurodegen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Kynurenic acid derivatives useful in the treatment of neurodegen will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1705722